RT Journal Article
T1 Promoting the ethical use of safe and effective cell-based products: the Andalusian plan on regenerative medicine.
A1 Cuende, Natividad
A1 Álvarez-Márquez, Antonia José
A1 Díaz-Aunión, Concepción
A1 Castro, Pablo
A1 Huet, Jesús
A1 Pérez-Villares, José Miguel
K1 direct-to-consumer marketing
K1 platelet-rich plasma
K1 point-of-care therapy
K1 regenerative medicine
K1 unproven stem cell treatments
K1 unregulated cell-based interventions
AB With regard to regenerative medicine, the expectations generated over the last two decades and the time involved in developing this type of therapies, together with the availability of devices that allow point-of-care treatments through the rapid isolation of cellular or plasma products from patients in the operating theater, represent the perfect breeding ground for the offering of unproven or unregulated therapies on a global scale. A multidisciplinary approach-one based on the collaboration of institutions that, from the perspective of their area of competence, can contribute to reversing this worrying situation-to this problem is essential. It is a priority for local health authorities to take measures that are adapted to the particular situation and regulatory framework of their respective territory. In this article, the authors present the regenerative medicine action plan promoted by the Andalusian Transplant Coordination (i.e., the action plan for the largest region in Spain), highlighting the aspects the authors believe are fundamental to its success. The authors describe, in summary form, the methodology, phases of the plan, actions designed, key collaborators, important milestones achieved and main lessons they have drawn from their experience so that this can serve as an example for other institutions interested in promoting the ethical use of this type of therapy.
YR 2020
FD 2020-08-30
LK http://hdl.handle.net/10668/16197
UL http://hdl.handle.net/10668/16197
LA en
DS RISalud
RD Apr 10, 2025